HAVCR2 and renal cell carcinoma: INCAGN02390 (as monotherapy) and MBG453 (as monotherapy or in combination with anti-PD-1) are, both of them, examples of anti-TIM3 antibodies currently being tested in RCC among other tumors [60,61].